Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

 Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Shots:

  • The first patient has been dosed in the P-I ANTLER trial evaluating CB-010 in patients with r/r B-NHL. In the dose-escalation part of the study, patients who have failed at least 2L of CT or immunotherapy will receive the therapy following lymphodepletion
  • The initial purpose of the dose escalation is to evaluate the safety & tolerability of CB-010 while an expansion part of the study is to evaluate the efficacy of CB-010 in a defined population. The results from the trial are expected in 2022
  • CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells which have developed using Caribou’s chRDNA CRISPR technology

Click here to read full press release/ article | Ref: Businesswire | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post